Privium Fund Management B.V. Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Privium Fund Management B.V. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,154 shares of the biopharmaceutical company’s stock after selling 20,829 shares during the quarter. Intra-Cellular Therapies comprises about 1.8% of Privium Fund Management B.V.’s portfolio, making the stock its 13th largest holding. Privium Fund Management B.V. owned approximately 0.09% of Intra-Cellular Therapies worth $8,114,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $32,000. GAMMA Investing LLC boosted its stake in Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. Finally, Quarry LP increased its stake in Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ITCI shares. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. StockNews.com started coverage on Intra-Cellular Therapies in a research report on Wednesday, March 12th. They issued a “hold” rating for the company. Finally, Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Price Performance

ITCI opened at $131.45 on Wednesday. The business has a fifty day moving average of $125.91 and a 200 day moving average of $96.52. Intra-Cellular Therapies, Inc. has a 52-week low of $63.87 and a 52-week high of $131.48. The stock has a market cap of $13.98 billion, a P/E ratio of -151.09 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.